JNJ-78934804

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Ulcerative ColitisCrohn's DiseaseColitis, UlcerativeCrohn Disease

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

1

Jyseleca

Gilead

Phase 3

62

Orencia

Bristol-Myers Squibb

Phase 3

13

Mounjaro

Eli Lilly

Phase 3

14

Icotyde

Johnson & Johnson

Phase 3

—5

Purinethol

SStason

Phase 3

16

SHR0302

RReistone Biopharma Company Limited

Phase 3

27

JNJ-78934804

Johnson & Johnson

Phase 3

48

JNJ-42756493

Johnson & Johnson

Phase 3

—9

ABX464

AAbivax S.A.

Phase 3

810

Ontamalimab

Takeda

Phase 3

4Show 30 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Colitis, Ulcerative2 trials

A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting·Johnson & Johnson·Phase 2·NCT05242484·577 enrolled

A Phase 3 Randomized, Double-blind, and Active Controlled, Multi-center Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting·Johnson & Johnson·Phase 3·NCT07577856·644 enrolled

Crohn's Disease1 trial

A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

Active, not recruiting·Johnson & Johnson·Phase 2·NCT05242471·703 enrolled

Crohn Disease1 trial

A Phase 3, Randomized, Double-blind, and Active-controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

Recruiting·Johnson & Johnson·Phase 3·NCT07577843·460 enrolled

Details

Drug Info

Related News